Jupiter Life Line Hospitals Ltd

Jupiter Life Line Hospitals Limited — Trading window closed from Oct 01, 2026 till 48 hours after the declaration of unaudited financial results (standalone & consolidated) for the quarter and half year ending Sept 30, 2026.

Jupiter Life Line Hospitals Ltd — Trading window closed from Oct 01, 2026 till 48 hours from the declaration of the Unaudited Financial Results (Standalone & Consolidated) of the Company to the Stock Exchanges for the quarter and half year ending on September 30, 2026.

Meeting Details

• Date and time: 28 September 2026, 1:00 pm–5:00 pm.
• Meeting type: investor conference, in-person.
• Organizer: PL Capital Conference.
• Participants: Company officials to attend.
• Purpose: investor conference discussions.
• Presentation materials will be available on the company's website.

Financial Performance

• Total income for Q1 FY27 stood at INR 411 crores.
• EBITDA was INR 79.3 crores with a 19.3% margin.
• PAT stood at INR 37.5 crores.
• ARPOB for the quarter was INR 73,500; ALOS 3.76 days.
• Occupancy was 59.6% this quarter, including expanded Dombivli beds.
• Dombivli completed its first full quarter with EBITDA drag of INR 9.5 crores.
• Three other operating hospitals and three upcoming projects are on track.

Operating Update

• Indore revenue grew about 10% YoY; higher HR costs due to expansion.
• Indore occupancy around 50%.
• Thane occupancy around mid-70%; Pune around mid-60%.
• Dombivli occupancy currently 25-30%.
• Fixed costs at Dombivli around INR 6-7 crores per month.
• Doctor hiring at Dombivli continues; ramp to add subspecialties.

Balance Sheet and Cash Flow

• Net debt is near zero; debt around INR 500 crores and cash around INR 500 crores.
• Board ceiling is 3x EBITDA; current capex to be funded within that range.
• Internal accruals expected to fund the next capex cycle.
• Pledge clarification: not promoter; corrected misreport due to split.

Projects and Capex

• Three existing hospitals and three upcoming projects are on track.
• IV fluids unit acquisition cost around INR 35-40 crores.
• Backward integration of pharmacy unit to improve margins.

Outlook and Guidance

• Dombivli EBITDA drag guidance: INR 2-3 crores per month.
• No aggressive revision yet; will update after 1-2 quarters.
• Inflation-linked growth expected for mature units; Indore occupancy to improve.

Q&A Highlights

• Unbilled revenue was a one-time policy change; future impact minimal.
• Dombivli occupancy currently 25-30%; empanelment should raise occupancy.
• Breakeven guidance for Dombivli remains; not aggressively revised yet.
• Location rationale: BKC premium area; accessible to many Mumbai residents.

Meeting Details

• Date and time: August 3, 2026 at 10:00 AM IST.
• Type and mode: Analyst/Investor Conference Call; virtual audio.
• Organizer: Jupiter Life Line Hospitals Limited.
• Key company participants: Company Secretary & Compliance Officer.
• Purpose: Earnings-related investor interaction for Q1 FY27 results.
• Availability: Audio recording of the conference call is available on the company's website.

Materiality authority and disclosure

• Board authorized MD & CEO Dr. Ankit Thakker and CFO Harshad Purani to determine materiality.
• The same officers are empowered to decide materiality of events for disclosure.
• Company Secretary and Compliance Officer Suma Upparatti is authorized for disclosures.
• Authority granted at board meeting held on 31 July 2026.
• Regulation reference: Regulation 30(5) of SEBI Listing Regulations 2015.
• Disclosure will be made to stock exchanges and posted on the company website.

Business Overview

• Core business: private multi-specialty hospitals; expanding at Dombivli, Pune II, Mira-Bhayandar, BKC.
• Strategy focuses on scaling bed capacity via phased commissioning.
• Insurance empanelment initiated to boost patient inflows.

Operational Highlights

• Q1FY27: Dombivli full-quarter operations with 200 beds; ramp-up loss ₹9.5 Cr.
• Bed capacity expansion plan: 500 Dombivli, 500 Pune II, 300 Mira-Bhayandar, 400 BKC.
• Total bed count target rising to 2,900 from 1,700.

Financial Performance

• Revenue from operations ₹392.6 Cr; total income ₹411.0 Cr in Q1FY27.
• YoY revenue growth: 16.2%; QoQ growth: 5.6%.
• EBITDA ₹79.3 Cr; EBITDA margin 19.3%.
• PBT ₹50.6 Cr; PAT ₹37.5 Cr; PBT margin 12.3%; PAT margin 9.1%.
• Depreciation increased due to capitalised beds; finance costs higher due to expansion debt.
• Internal cash flow to EBITDA conversion ~75-80% over five years.

Capital Structure & Liquidity

• Funding philosophy: internal accruals to fund expansion capex.
• Finance costs rose with debt for expansion.

Strategic Priorities & Outlook

• Phased commissioning to optimize capital deployment.
• Strategic land bank in high-demand micro markets.
• Scale bed capacity toward 2,900 beds to drive operating leverage.

Risks & Mitigation

• Ramp-up delays and higher marketing costs during launch.
• Debt-related financing risk mitigated by phased capex and internal accruals.

Governance & Leadership

• MD & CEO Dr. Ankit Thakker highlighted ramp-up progress.
• No governance changes disclosed.

Acquisition of Sulcus Private Limited

• Target: Sulcus Private Limited, in IV fluids, infusions and pharmaceutical manufacturing in India.
• Size/scale: NIL turnover; 10,000 equity shares; cash price ₹3.78 crore.
• Related party: Promoter group comprising Dr Ankit Thakker and Mrs K Thakker; arm's length, independent valuation.
• Industry: Pharmaceuticals; impact: JHPPL to set up IV fluids and manufacturing facility near Ujjain.
• Approval: DMIC Vikram Udyogpuri Limited permission received.
• Timeline: SPA signed on July 31, 2026.
• Consideration: Cash; ₹3.78 crore.
• Shareholding: 100% of paid-up equity (10,000 shares) acquired.
• Background: Sulcus incorporated 23/08/2012; NIL turnover; land near Ujjain, MP, India.
• Rationale: Aligns with Jupiter Hospitals expansion; reduce costs; margins via new manufacturing facility.

Target company

• Target company: Jupiter Life Line Hospitals Limited.

Disclosing party

• Acquirer: Catalyst Trusteeship Limited (Debenture Trustee); not promoter group.

Transaction type

• Release of encumbrance on pledged shares.

Pre-transaction holding

• Encumbered shares: 33,51,950 (5.11%); voting rights: none.

Transaction details

• Released encumbrance on 1,67,59,750 shares; 5.11% of total; due to stock split; date July 25, 2026.

Post-transaction holding

• Encumbered shares after: 1,67,59,750 (5.11%); voting rights: none.

Date of transaction

• Date of transaction: July 25, 2026.

Share capital context

• Capital before/after: Rs 65,56,60,220; diluted capital not disclosed.